Related Experiment Video

Updated: May 14, 2026

A Minimally Invasive Model of Aortic Stenosis in Swine
06:51

A Minimally Invasive Model of Aortic Stenosis in Swine

Published on: October 20, 2023

Aortic stenosis: a general overview of clinical, pathophysiological and therapeutic aspects

Finn Akerström1, Maria G Barderas, Luis Rodríguez-Padial

  • 1Department of Cardiology, Hospital Virgen de la Salud, Toledo, Spain.

Expert Review of Cardiovascular Therapy
|February 15, 2013
PubMed

Insights

Calcific aortic valve disease (CAVD) is a common heart condition. Current treatments are limited, highlighting the need for new therapies to slow CAVD progression and reduce valve replacement needs.

Area of Science:

  • Cardiovascular Medicine
  • Valvular Heart Disease
  • Biomedical Research

Background:

  • Aortic stenosis is the most common heart valve disease, frequently caused by calcific aortic valve disease (CAVD).
  • CAVD shares similarities with atherosclerosis, involving active disease processes and cardiovascular risk factors.
  • Current treatment primarily involves valve replacement, necessitating the development of pharmacological interventions.

Purpose of the Study:

  • To explore the potential of pharmacological therapies for retarding calcific aortic valve disease progression.
  • To identify novel disease biomarkers and therapeutic strategies for CAVD.
  • To reduce the reliance on surgical valve replacement for aortic stenosis.

Main Methods:

  • Review of existing evidence on CAVD pathogenesis and risk factors.
  • Analysis of previous research on lipid-lowering therapies for CAVD.
  • Proposal for future studies utilizing animal models to investigate CAVD mechanisms.

Main Results:

  • Lipid-lowering therapies have thus far yielded negative results in treating CAVD.
  • CAVD is an active disease process with mechanisms comparable to atherosclerosis.
  • Pharmacological interventions are needed to manage CAVD progression.

Conclusions:

  • There is a critical need for pharmacological treatments to slow the progression of calcific aortic valve disease.
  • Future research, including animal studies, is essential for understanding CAVD mechanisms and identifying effective therapies.
  • Discovering biomarkers and new drug targets could significantly decrease the need for aortic valve replacement.

More Related Videos

A Rabbit Aortic Valve Stenosis Model Induced by Direct Balloon Injury07:10

A Rabbit Aortic Valve Stenosis Model Induced by Direct Balloon Injury

Published on: March 31, 2023

Related Concept Videos

Aortic Regurgitation I: Introduction01:15

Aortic Regurgitation I: Introduction

IntroductionAortic regurgitation is characterized by the backward flow of blood from the aorta into the left ventricle during diastole and arises from the improper closure of the aortic valve. This condition results in left ventricular volume overload and can stem from both acute and chronic etiologies, each contributing uniquely to the disease's progression and symptomatology.Acute and Chronic CausesAcute aortic regurgitation often results from events that suddenly impair the integrity of the...
Aortic Regurgitation III: Medical Management01:25

Aortic Regurgitation III: Medical Management

Aortic regurgitation (AR) is when the aortic valve does not close or seal properly, leading to backward blood circulation from the aorta into the left ventricle during diastole. Common causes of AR include rheumatic heart disease, congenital valve defects, and aortic root dilation. Managing AR requires a multifaceted approach to alleviate symptoms, preserve left ventricular function, and address the underlying cause of the regurgitation. Patients with symptomatic AR or significant left...
Mitral Stenosis II: Clinical features and Diagnostic Tests01:23

Mitral Stenosis II: Clinical features and Diagnostic Tests

Mitral stenosis is a heart condition in which the mitral valve, which allows blood to flow from the left atrium to the left ventricle, becomes narrowed or stenotic. This narrowing hinders blood flow and leads to clinical symptoms requiring specific medical evaluations and management strategies. The following overview outlines the clinical symptoms, assessments, diagnostic findings, prevention methods, and treatments for mitral stenosis.Clinical ManifestationsDyspnea (shortness of breath): This...
Mitral Stenosis III: Medical Management01:26

Mitral Stenosis III: Medical Management

Mitral stenosis, a condition marked by the narrowing of the mitral valve, necessitates an integrated approach for effective management. This approach includes preventative measures, medical therapy, and surgical interventions to reduce symptoms and prevent complications.PreventionPrevention of mitral stenosis primarily focuses on reducing the incidence of bacterial infections, particularly streptococcal infections, which can lead to rheumatic fever and subsequent valvular damage. Timely...
Mitral Stenosis I: Introduction01:22

Mitral Stenosis I: Introduction

Mitral Valve Stenosis (MVS) is a heart condition where the mitral valve narrows, impeding blood circulation from the left atrium to the left ventricle. The etiology and pathophysiology of this condition are multifaceted, leading to a cascade of cardiovascular complications.Causes of Mitral Valve StenosisRheumatic Heart Disease: It is the main cause of mitral valve stenosis, particularly in developing nations. This condition arises from rheumatic fever, an inflammatory illness resulting from...
Aneurysm I: Introduction01:30

Aneurysm I: Introduction

An aortic aneurysm is a localized outpouching or dilation at a weak point in the artery wall. It may involve different parts of the aorta, such as the abdominal aorta, aortic arch, or thoracic aorta.Etiological factorsSeveral disorders are associated with aortic aneurysms.Congenital causes, such as primary connective tissue disorders like Marfan syndrome, impact the integrity and strength of connective tissues, notably affecting the aorta. Marfan syndrome is a genetic disorder that specifically...